Dupilumab SAR231893
EFC16461
Phase 3 small_molecule completed
Quick answer
Dupilumab SAR231893 for Chronic Spontaneous Urticaria is a Phase 3 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Chronic Spontaneous Urticaria
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed